English  |  正體中文  |  简体中文  |  總筆數 :0  
造訪人次 :  51124206    線上人數 :  741
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

"ann lii cheng"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 511-520 / 690 (共69頁)
<< < 47 48 49 50 51 52 53 54 55 56 > >>
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2021-08-31T06:29:19Z Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYnote-240: A Randomized, Double-Blind, Phase III Trial Finn R.S.; Ryoo B.-Y.; Merle P.; Kudo M.; Bouattour M.; Lim H.Y.; Breder V.; Edeline J.; Chao Y.; Ogasawara S.; Yau T.; Garrido M.; Chan S.L.; Knox J.; Daniele B.; Ebbinghaus S.W.; Chen E.; Siegel A.B.; Zhu A.X.; ANN-LII CHENG; KEYnote-240 investigators
臺大學術典藏 2021-08-31T06:29:19Z Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma ANN-LII CHENG; Hsu C.; Chan S.L.; Choo S.-P.; Kudo M.
臺大學術典藏 2021-08-31T06:29:18Z Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO Chen L.-T.; Martinelli E.; ANN-LII CHENG; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Shen Y.-C.; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y.
臺大學術典藏 2021-08-31T06:29:18Z Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; ANN-LII CHENG; Kuo S.-H.
臺大學術典藏 2021-08-31T06:29:18Z Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:17Z Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma Kelley R.K.; Mollon P.; Blanc J.-F.; Daniele B.; Yau T.; ANN-LII CHENG; Valcheva V.; Marteau F.; Guerra I.; Abou-Alfa G.K.
臺大學術典藏 2021-08-31T06:29:17Z Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma Finn R.S.; Qin S.; Ikeda M.; Galle P.R.; Ducreux M.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.O.; Li D.; Verret W.; Xu D.-Z.; Hernandez S.; Liu J.; Huang C.; Mulla S.; Wang Y.; Lim H.Y.; Zhu A.X.; ANN-LII CHENG; IMbrave150 Investigators
臺大學術典藏 2021-08-31T06:29:17Z Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival Chen T.W.-W.; Jan I.-S.; Chang D.-Y.; Lin C.-H.; Chen I.-C.; Chen H.-M.; ANN-LII CHENG; Lu Y.-S.
臺大學術典藏 2021-08-31T06:29:17Z IMbrave 050: A Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation Hack S.P.; Spahn J.; Chen M.; ANN-LII CHENG; Kaseb A.; Kudo M.; Lee H.C.; Yopp A.; Chow P.; Qin S.
臺大學術典藏 2021-08-31T06:29:17Z A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements Kudo M.; Han K.-H.; Ye S.-L.; Zhou J.; Huang Y.-H.; Lin S.-M.; Wang C.-K.; Ikeda M.; Chan S.L.; Choo S.P.; Miyayama S.; ANN-LII CHENG

顯示項目 511-520 / 690 (共69頁)
<< < 47 48 49 50 51 52 53 54 55 56 > >>
每頁顯示[10|25|50]項目